These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 18089388)

  • 1. Prediction of nonrelapse mortality for patients surviving 100 days after allogeneic hematopoietic stem cell transplantation.
    Wojnar J; Giebel S; Holowiecka-Goral A; Markiewicz M; Wylezol I; Kopera M; Krawczyk-Kulis M; Holowiecki J
    Transplant Proc; 2007 Dec; 39(10):3375-9. PubMed ID: 18089388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe infections after unrelated donor allogeneic hematopoietic stem cell transplantation in adults: comparison of cord blood transplantation with peripheral blood and bone marrow transplantation.
    Parody R; Martino R; Rovira M; Vazquez L; Vázquez MJ; de la Cámara R; Blazquez C; Fernández-Avilés F; Carreras E; Salavert M; Jarque I; Martín C; Martínez F; López J; Torres A; Sierra J; Sanz GF;
    Biol Blood Marrow Transplant; 2006 Jul; 12(7):734-48. PubMed ID: 16785063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
    Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preengraftment serum C-reactive protein (CRP) value may predict acute graft-versus-host disease and nonrelapse mortality after allogeneic hematopoietic stem cell transplantation.
    Fuji S; Kim SW; Fukuda T; Mori S; Yamasaki S; Morita-Hoshi Y; Ohara-Waki F; Heike Y; Tobinai K; Tanosaki R; Takaue Y
    Biol Blood Marrow Transplant; 2008 May; 14(5):510-7. PubMed ID: 18410893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum cholestasis markers as predictors of early outcome after liver transplantation.
    Ben-Ari Z; Weiss-Schmilovitz H; Sulkes J; Brown M; Bar-Nathan N; Shaharabani E; Yussim A; Shapira Z; Tur-Kaspa R; Mor E
    Clin Transplant; 2004 Apr; 18(2):130-6. PubMed ID: 15016125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantation.
    Nevill TJ; Shepherd JD; Sutherland HJ; Abou Mourad YR; Lavoie JC; Barnett MJ; Nantel SH; Toze CL; Hogge DE; Forrest DL; Song KW; Power MM; Nitta JY; Dai Y; Smith CA
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):205-13. PubMed ID: 19167680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO).
    Patriarca F; Bacigalupo A; Sperotto A; Isola M; Soldano F; Bruno B; van Lint MT; Iori AP; Santarone S; Porretto F; Pioltelli P; Visani G; Iacopino P; Fanin R; Bosi A;
    Haematologica; 2008 Oct; 93(10):1514-22. PubMed ID: 18728030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
    Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early and late neurological complications after reduced-intensity conditioning allogeneic stem cell transplantation.
    Barba P; Piñana JL; Valcárcel D; Querol L; Martino R; Sureda A; Briones J; Delgado J; Brunet S; Sierra J
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1439-46. PubMed ID: 19822304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of pretransplantation serum ferritin on nonrelapse mortality after myeloablative and nonmyeloablative allogeneic hematopoietic stem cell transplantation.
    Kataoka K; Nannya Y; Hangaishi A; Imai Y; Chiba S; Takahashi T; Kurokawa M
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):195-204. PubMed ID: 19167679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of race on survival after stem cell transplantation.
    Mielcarek M; Gooley T; Martin PJ; Chauncey TR; Young BA; Storb R; Torok-Storb B
    Biol Blood Marrow Transplant; 2005 Mar; 11(3):231-9. PubMed ID: 15744242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of readmission in children receiving allogeneic hematopoietic stem cell transplantation: an institutional experience.
    Jaing TH; Tsay PK; Yang CP; Hung IJ; Wen YC; Tseng CK
    Transplant Proc; 2008 Dec; 40(10):3643-5. PubMed ID: 19100457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine.
    Mori T; Aisa Y; Watanabe R; Yamazaki R; Kato J; Shimizu T; Shigematsu N; Kubo A; Yajima T; Hibi T; Ikeda Y; Okamoto S
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):651-7. PubMed ID: 18489990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years.
    Huisman C; Meijer E; Petersen EJ; Lokhorst HM; Verdonck LF
    Biol Blood Marrow Transplant; 2008 Feb; 14(2):181-6. PubMed ID: 18215778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation.
    Kyriakou C; Canals C; Finke J; Kobbe G; Harousseau JL; Kolb HJ; Novitzky N; Goldstone AH; Sureda A; Schmitz N
    J Clin Oncol; 2009 Aug; 27(24):3951-8. PubMed ID: 19620487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of hematopoietic stem cell transplantation after treatment with different high-dose total-body irradiation regimens in five Dutch centers.
    van Kempen-Harteveld ML; Brand R; Kal HB; Verdonck LF; Hofman P; Schattenberg AV; van der Maazen RW; Cornelissen JJ; Eijkenboom WM; van der Lelie JP; Oldenburger F; Barge RM; van Biezen A; Vossen JM; Noordijk EM; Struikmans H
    Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1444-54. PubMed ID: 18294781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors and mortality predictors of hepatic veno-occlusive disease after pediatric hematopoietic stem cell transplantation.
    Cheuk DK; Wang P; Lee TL; Chiang AK; Ha SY; Lau YL; Chan GC
    Bone Marrow Transplant; 2007 Nov; 40(10):935-44. PubMed ID: 17768390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic kidney dysfunction in patients alive without relapse 2 years after allogeneic hematopoietic stem cell transplantation.
    Abboud I; Porcher R; Robin M; de Latour RP; Glotz D; Socié G; Peraldi MN
    Biol Blood Marrow Transplant; 2009 Oct; 15(10):1251-7. PubMed ID: 19747632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognosis in transplant-eligible patients with agnogenic myeloid metaplasia: a simple CBC-based scoring system.
    Dingli D; Schwager SM; Mesa RA; Li CY; Tefferi A
    Cancer; 2006 Feb; 106(3):623-30. PubMed ID: 16369987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting survival in adults with invasive aspergillosis during therapy for hematological malignancies or after hematopoietic stem cell transplantation: Single-center analysis and validation of the Seattle, French, and Strasbourg prognostic indexes.
    Parody R; Martino R; Sánchez F; Subirá M; Hidalgo A; Sierra J
    Am J Hematol; 2009 Sep; 84(9):571-8. PubMed ID: 19676118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.